sequence under fasting conditions and at least 7 days washout period between the doses.,A randomized&#44

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Pregabalin 150 mg hard capsules relative to Lyrica(TM) capsule 150 mg in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Voriconazole 200 mg tablets relative to Vfend(R) 200 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, fully replicate crossover design with four-period, two-treatment and two-sequence of Atorvastatin 80 mg tablets relative to Lipitor(R) 80 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Sitagliptin 100 mg plain tablets manufactured by Medochemie Ltd., relative to Januvia® 100 mg tablets - MSD in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban Film-coated tablets (5 mg) relative to Originator Apixaban Film-coated tablets (5 mg) in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Olmesartan medoxomil 40 mg tablets relative to Olmetec® in healthy Thai volunteers under fasting condition (A Pilot Study)

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Alfuzosin XR 10 mg tablets relative to Xatral® XL 10 mg tablets in healthy Thai male volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rivaroxaban Tablet (10 mg) relative to Xarelto® 10 mg in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levetiracetam Tablet (500 mg) relative to KEPPRA® TABLET (500 mg) (Original Levetiracetam Tablet (500 mg)) in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Tamsulosin Hydrochloride, 0.4 mg prolonged release tablets relative to Harnal OCAS® 0.4 mg tablets in healthy Thai male volunteers under fed condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Celecoxib 400 mg capsules relative to Celebrex® 400 mg capsules in healthy Thai volunteers under fasting condition

Bioequivalence evaluation of test and reference formulations of Voriconazole 200 mg tablets administered to 38 healthy volunteers after single dose (2-Period, 2-Treatment, 2-Sequence, 2-Way, Crossover Study under fasting condition)

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levocetirizine 5 mg relative to Xyzal® 5 mg tablets in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Celecoxib Capsule (200 mg) relative to CELEBREX CAPSULE 200 MG in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single oral dose, 3-period, 2-treatment, 3-sequence, partial replicate, crossover study of Atorvastatin 40 mg tablets relative to Lipitor(R) 40 mg tablets in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Celecoxib Capsule (400 mg) relative to CELEBREXTM (Original Celecoxib Capsule (400 mg)) in healthy Thai volunteers under fasting condition